What is Denosumab and what are the notable side effects ?

Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor kappa-B (RANK) ligand, preventing activation of RANK, which disrupts osteoclast maturation and activation.

The most common adverse event overall was hypocalcemia, which occurred in 5% of patients despite supplementation with vitamin D and calcium. 

The most common severe adverse event was hypophosphatemia, which occurred in 3% of patients.

Osteonecrosis of the jaw is an infrequent but serious complication of treatment with denosumab.